Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Click on image to see Patient Registry in Review 2018 The Life Raft Group has played an instrumental role in bridging the gap between patients with valuable clinical Gastrointestinal Stromal Tumor (GIST) [...]
PDF is available of LRG Science to print here. Real World Evidence in Action Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges [...]
Senior Director of Program Operations, Sara Rothschild, recently represented the Life Raft Group at the SPAEN (Sarcoma Patients EuroNet) meeting. Subsequent to the meeting, over 300 medical professionals gathered for the 7th annual ESMO [...]
Columbia University Medical Center, New York-Presbyterian and the Life Raft Group have entered into a collaborative effort to advance research to find a cure for GIST using a novel therapeutic approach and patient-driven data. [...]
The Life Raft Group became a formal non-profit on June 10, 2002. Begun as a grass roots effort by a group of men and women with a deadly cancer in 2000, by the year [...]
The latest edition of the GIST and Sarcoma Journal is now available online. The GIST and Sarcoma Journal is a comprehensive and authoritative resource for scientifically valid information for physicians, allied healthcare professionals [...]
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
This article originally appeared in the January 30th edition of Cure Today. Less than two decades ago, Gleevec (imatinib) drastically changed the frontline treatment for patients with gastrointestinal stromal tumors (GIST). However, as patients [...]
A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]
